1. In patients with diabetes/ impaired glucose tolerance (DM/IGT), the mean change in AUC glucose as compared between relacorilant and placebo arm (Time Frame - Baseline to week 22)
2. In patients with systolic hypertension, the change in mean systolic blood pressure (SBP) based on 24-hour ambulatory blood pressure monitor (ABPM) as compared between relacorilant and placebo arms (Time Frame - Baseline to week 22)
3. Rate of safety based TEAEs (Time Frame - Baseline to week 22): Assessment of safety based on treatment-emergent adverse events (TEAEs) as graded by CTCAE v5.0.
Secondary outcome:
1. In patients with DM at baseline the mean change in HbA1c and fasting glucose (Time Frame - Baseline to week 22/ET)
2. Proportion of patients with IGT at Baseline who achieved normalization of 2-hour oGTT glucose (Time Frame - Week 22/ET)
3. Proportion of patients with normalization of the mean SBP (Time Frame - Baseline to week 22/ET)
Experimental: Relacorilant The dose of relacorilant will be increased sequentially from 100 mg orally once daily to a target dose of 400 mg once daily.
Placebo Comparator: Placebo Placebo matched to study drug
